[Methylphenidate in the treatment of children with attention-deficit hyperactivity disorder: monitoring in biological matrices].
Attention-deficit hyperactivity disorder (ADHD) has emerged in the last few years as the most commonly diagnosed and treated psychiatric disorder in the paediatric population. In 1980's, methylphenidate (MFD) a psychomotor stimulant drug, was approved in Spain for the symptomatic therapy of ADHD. Since then, MFD has become one of the most extensively prescribed and studied treatment for ADHD both in children and adults. In this paper, the main pharmacological issues of MFD are reviewed, focusing on its pharmacokinetics in conventional (blood and urine) and non-conventional (hair, oral fluid and sweat) biological matrices, its pharmaceutical preparations, therapeutic levels and side effects.
Grup de Recerca Clínica en Farmacología Humana i Neurociències, Programa de Neurociencias, Institut Municipal d'Investigació Mèdica, Barcelona, Spain.
E
E
Papaseit
O
O
García-Algar
S
S
Simó
S
S
Pichini
M
M
Farré
D000293:Adolescent; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D002648:Child; D018765:Dopamine Uptake Inhibitors / Q000097:blood / Q000627:therapeutic use* / Q000652:urine; D016903:Drug Monitoring / Q000379:methods; D006801:Humans; D008774:Methylphenidate / Q000097:blood / Q000627:therapeutic use* / Q000652:urine
D018765:Dopamine Uptake Inhibitors; D008774:Methylphenidate